Conversio Health

Conversio Health is a pioneering chronic condition management company aiming to enhance care, adherence, and cost associated with chronic respiratory conditions. The company has distinguished itself by providing a novel approach to chronic respiratory condition management, harnessing proprietary technologies and customized nebulizer medication therapies. Conversio Health collaborates with a multidisciplinary care team to achieve improved clinical and financial outcomes, as well as higher patient satisfaction. The company's high-touch pharmacy model encompasses home delivery services, personalized patient education, and support, as well as disease progression and medication effectiveness monitoring to proactively prevent hospitalizations. This approach enables a higher level of care coordination across the care continuum, thereby lowering health plan partners' drug costs and enhancing clinical outcomes for thousands of COPD and Asthma patients across the United States. Founded in 2013 and headquartered in San Luis Obispo, California, Conversio Health operates within the Biotechnology and Health Care industries. It secured a substantial $12.43M Venture Round investment on 09 February 2024. The company's investor information is not available. In summary, Conversio Health exemplifies innovation in chronic condition management through its unique pharmacy model and emphasis on care coordination, demonstrating promising potential for improved patient outcomes and cost savings.